Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-17
2011-11-22
Aulakh, Charanjit (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S105000
Reexamination Certificate
active
08063062
ABSTRACT:
Embodiments of this invention relate to compounds having a combination of cannabinoid-CB1antagonism and cholinesterase inhibition, to pharmaceutical compositions comprising these compounds, to methods for preparing these compounds, methods for preparing novel intermediates useful for the synthesis of these compounds, and methods for preparing compositions comprising these compounds. The invention also relates to methods of treating Alzheimer's disease, cognitive disorders, memory disorders, dementia, attention deficit disorder, traumatic brain injury, drug dependence, addiction or substance abuse by administering a pharmaceutical composition comprising these compounds to a patient in need thereof. A compound with a combination of cannabinoid-CB1antagonism and cholinesterase inhibition is a compound of formula (1)wherein the symbols have the meanings given in the specification.
REFERENCES:
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/063781 (2003-08-01), None
patent: WO 2004/013120 (2004-02-01), None
patent: WO 2005/037199 (2005-04-01), None
patent: WO 2005/118553 (2005-12-01), None
patent: WO 2006/061372 (2006-06-01), None
patent: WO 2006/061374 (2006-06-01), None
patent: WO 2006/061376 (2006-06-01), None
Lange et al., “Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB1 Cannabinoid Receptor Antagonists,” Medicinal Chemistry, vol. 47, No. 3, 2004, pp. 627-643, XP001188902, ISSN.
Carlier et al., “Heterodimeric Tacrine-Based Acetylcholinesterase Inhibitors: Investigating Ligand-Peripheral Site Interactions,” Medicinal Chemistry, vol. 42, No. 20, pp. 4225-4231, XP002434602 (1999).
Morphy et al., “Designed Multiple Ligands. An Emerging Drug Discovery Paradigm,” Medicinal Chemistry, vol. 48, No. 21, pp. 6523-6543, XP002434603, (2005).
International Search Report and Written Opinions, both dated Mar. 13, 2008, issued in PCT/EP2007/064169 and PCT/EP2008/050181.
Consroe, “Brain Cannaboinoid Systems as Targets for the Therapy of Neurological Disorders,”Neurobiology of Disease5, 534-551, 545 (1998).
Keowkase et al., “Mechanism of CNS Drugs and their Combinations for Alzheimer's Disease,”Central Nervous System Agents in Medicinal Chemistry, 2008, 8, 241-248, 241.
Griffin et al., “A Review of Cholinergic Agents in the Treatment of Neurobehavioral Deficits Following Traumatic Brain Injury,” J. Neuropsychiatry Clin. Neurosci 15:1, Winter 2003, 17-26.
Pertwee, R., “Neuropharmacology and therapeutic potential of cannabinoids,” Addiction Biology (2000), 5, 37-46.
Masanic et al., “Open-Label Study of Donepezil in Traumatic Brain Injury,” Arch. Phys. Med. Rehabil. vol. 82, Jul. 2001.
Hikida et al, Acetylcholine enhancement in the nucleus accumbens prevents additive behaviors of cocaine and morphine, Proceedings of the National Acadamy of Sciences of the United States of America May 13, 2003, vol. 1000, No. 10, 6169-6173.
Cohen et al., “CB1receptor antagonists for the treatment of nicotine addiction,”Pharmacology, Biochemistry and Behavior81 (2005) 387-395.
Foll et al., “Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence,” The Journal of Pharmacology and Experimental Therapeutics, vol. 312 (2005) 875-883.
Tzavara et al., “The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions,” British Journal of Pharmacology (2003) 138, 544-553 (2003).
Tenovuo, Cholinergic Treatment of Traumatic Brain Injury, Current Drug Therapy, 2006, 1, 187-209.
Kruse Cornelis G.
Lange Josephus H. M.
Shadid Belal
Aulakh Charanjit
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Solvay Pharmaceuticals B.V.
LandOfFree
Compounds with a combination of cannabinoid-CB 1 antagonism... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds with a combination of cannabinoid-CB 1 antagonism..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds with a combination of cannabinoid-CB 1 antagonism... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4307564